Ortiz A.,Associated Unit to CSIC |
Domenech O.,Associated Unit to CSIC |
Munoz-Juncosa M.,Associated Unit to CSIC |
Prat J.,Associated Unit to CSIC |
And 4 more authors.
Colloids and Surfaces A: Physicochemical and Engineering Aspects | Year: 2015
Langmuir-Blodgett films (LBs) and supported lipid bilayers (SLBs) of dimyristoylphosphatidylcholine (DMPC)-dimyristoylphosphatidylserine (DMPS) (3:2) were used to investigate the way that a GBV-C peptide (P45) inhibits the immunodeficiency human virus fusion peptide (HIV-1 FP) action at membrane level. Supported lipid bilayers (SLBs) were prepared by direct adsorption of a liposomal dispersion on solid mica slides and Langmuir-Blodgett films (LBs) by a deposition of a monolayer onto mica solid surface at different compression pressures. The behaviour of P45, HIV-1 FP and a mixture of P45 and HIV-1 FP (1:1) were monitored in the two phospholipid membrane models by fluorescence microscopy (FM) and atomic force microscopy (AFM). Experiments with SLBs confirmed that P45 inhibited HIV-1 FP action in vitro. LBs obtained at 10 and 25mNm-1 confirmed different lipid interactions for DMPC/DMPS (3:2) in combination with either P45 (8:2), HIV-1 FP (8:2), or P45 and HIV-1 FP (8:1:1). The P45 peptide was confirmed to modulate the action of HIV-1 FP. Furthermore, FM and AFM images showed that HIV-1 FP had a pressure-independent membrane-level behaviour when compared with P45 and the P45+HIV-1 FP (1:1) mixture. This mixture also had dramatic effects on the appearance of liquid expanded (LE)-liquid condensed (LC) phase coexistence as shown by FM and AFM. © 2015 Elsevier B.V. Source